Yahoo Movies
Salma Hayek, 54, zens out in black string bikini
Salma Hayek, 54, shared yet another bikini photo on Tuesday. Posing both in and out of the water beachside, apparently finding zen in both places, she wrote, “We need to keep our cool.”
Salma Hayek, 54, shared yet another bikini photo on Tuesday. Posing both in and out of the water beachside, apparently finding zen in both places, she wrote, “We need to keep our cool.”
Most of the poses also focus more on your back and helps your whole body to relax and not feel its effects like stress.
The housebuilder is is putting aside £20.9 million after uncovering another 10 buildings that may need cladding replacement.
Big tax rises in the Budget are "screeching U-turns on Conservative policy", says the Institute for Fiscal Studies.
The European Commission on Thursday announced goals for the 27-nation bloc to reduce poverty, inequality and boost training and jobs by 2030 as part of a post-pandemic economic overhaul financed by jointly borrowed funds. The goals, which will have to be endorsed by EU leaders, also include an increase in the number of adults getting training every year to adapt to the EU's transition to a greener and more digitalised economy to 60% from 40% now. Finally, over the next 10 years, the EU should reduce the number of people at risk of poverty or social exclusion by 15 million from 91 million in 2019.
The Duke of Edinburgh, 99, has been in the hospital for more than two weeks.
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "2021 Isoflavones Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive research with in-depth data and contemporary analysis of Isoflavones Market at a global, regional and key country level, split by different sub-segments of the industry. The report presents growth projections in the Isoflavones Market between 2021 and 2027 for companies operating across different types, applications, and end-user verticals.Isoflavones Market is quickly reaching its pre-COVID levels and a healthy growth rate is expected over the forecast period driven by the V-shaped recovery in most of the developing nations.Key strategies of companies operating in Isoflavones Market Industry are identified as showcasing their contactless manufacturing and delivery methods, highlighting USP statements, focus on product packaging, and increased the presence of products on online platforms.The food industry is set to experience a few changes in 2021 due to the increased consciousness of consumers in selecting food. This inclination towards sustainable, regenerative, plant-based food and demand for foods and beverages with immunity-boosting ingredients is driving the demand for these products and their constituents. Do It Yourself (DIY) trend has seen huge momentum during Corona times and is expected to continue in 2021.Considering the rapidly changing market landscape, companies are changing their perspectives on expanding beyond traditional markets. In addition to focusing on widening applications, introducing new product portfolios, most food and beverage companies are planning to capture domestic and international markets.Fast pace recovery of developing economies leading to increased disposable income will support the Isoflavones Market demand between 2021 and 2027.Lockdowns across the globe in 2020 and continuing restrictions in 2021 disrupted the supply chain posing challenges for manufactures in the Isoflavones Market. Intense competition, pricing issues, and shifting consumer preferences will continue to put pressure on vendors' profit margins.Short-term and long-term trends affecting the market landscape are included in the research. Further, market drivers, restraints, and potential opportunities are also provided in the report.The Isoflavones report computes the 2020 market value in revenue terms based on the average Isoflavones prices and sales/revenue models of key companies operating in the Isoflavones Market Industry. The study forecasts the market size to 2027 for different types of Isoflavones and provides respective market share and growth rates.The study discusses technological innovations and the potential shift in demand among various products in the Isoflavones Market, over the forecast period. The leading five companies in the Isoflavones Market Industry together with their products, key strategies, and comparisons are provided.The Isoflavones Market size, share, and outlook across different types and applications are provided at geographic levels of North America, Asia Pacific, Europe, Middle East Africa, South and Central America. Further, country-level Isoflavones Market value is also provided.All recent developments in Isoflavones Market Industry including mergers, acquisitions, contract awards, licenses, product launches, and expansion plans are included in the report. Base Year - 2020; Forecast period: 2021 - 2027Publication frequency - Every six monthsResearch Methodology - Data triangulation with top-down and Bottom-up approach are used for market size Scope of the Report Global Isoflavones Market Industry size, 2020-2027Market trends, drivers, restraints, and opportunitiesPorter's Five forces analysisTypes of Isoflavones, 2020-2027Isoflavones applications and end-user verticals market size, 2020-2027Isoflavones Market size across countries, 2020-20275 leading companies in the industry - overview, key strategies, financials, and productsLatest market news and developments Key Topics Covered: 1. Table of Contents2. Isoflavones Market Latest Trends, Drivers and Challenges, 2020 -20272.1 Isoflavones Market Overview2.2 Post COVID Strategies of Leading Isoflavones Companies2.3 Isoflavones Market Insights, 2021-20272.3.1 Leading Isoflavones types, 2021-20272.3.2 Leading Isoflavones End-User industries, 2021-20272.3.3 Fast-Growing countries for Isoflavones sales, 2021-20272.4 Isoflavones Market Drivers and Restraints2.4.1 Isoflavones Demand Drivers to 20272.4.2 Isoflavones Challenges to 20272.5 Isoflavones Market-Five Forces Analysis2.5.1 Isoflavones Industry Attractiveness Index, 20202.5.2 Threat of New Entrants2.5.3 Bargaining Power of Suppliers2.5.4 Bargaining Power of Buyers2.5.5 Intensity of Competitive Rivalry2.5.6 Threat of Substitutes3. Global Isoflavones Market Value, Market Share, and Forecast to 20273.1 Global Isoflavones Market Overview, 20203.2 Global Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)3.3 Global Isoflavones Market Size and Share Outlook by Type, 2021-20273.4 Global Isoflavones Market Size and Share Outlook by End-User, 2021-20273.5 Global Isoflavones Market Size and Share Outlook by Region, 2021-20274. Asia Pacific Isoflavones Market Value, Market Share and Forecast to 20274.1 Asia Pacific Isoflavones Market Overview, 20204.2 Asia Pacific Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)4.3 Asia Pacific Isoflavones Market Size and Share Outlook by Type, 2021-20274.4 Asia Pacific Isoflavones Market Size and Share Outlook by End-User, 2021-20274.5 Asia Pacific Isoflavones Market Size and Share Outlook by Country, 2021-20274.6 Key Companies in Asia Pacific Isoflavones Market5. Europe Isoflavones Market Value, Market Share, and Forecast to 20275.1 Europe Isoflavones Market Overview, 20205.2 Europe Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)5.3 Europe Isoflavones Market Size and Share Outlook by Type, 2021-20275.4 Europe Isoflavones Market Size and Share Outlook by End-User, 2021-20275.5 Europe Isoflavones Market Size and Share Outlook by Country, 2021-20275.6 Key Companies in Europe Isoflavones Market6. North America Isoflavones Market Value, Market Share and Forecast to 20276.1 North America Isoflavones Market Overview, 20206.2 North America Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)6.3 North America Isoflavones Market Size and Share Outlook by Type, 2021-20276.4 North America Isoflavones Market Size and Share Outlook by End-User, 2021-20276.5 North America Isoflavones Market Size and Share Outlook by Country, 2021-20276.6 Key Companies in North America Isoflavones Market7. South and Central America Isoflavones Market Value, Market Share and Forecast to 20277.1 South and Central America Isoflavones Market Overview, 20207.2 South and Central America Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)7.3 South and Central America Isoflavones Market Size and Share Outlook by Type, 2021-20277.4 South and Central America Isoflavones Market Size and Share Outlook by End-User, 2021-20277.5 South and Central America Isoflavones Market Size and Share Outlook by Country, 2021-20277.6 Key Companies in South and Central America Isoflavones Market8. Middle East Africa Isoflavones Market Value, Market Share and Forecast to 20278.1 Middle East Africa Isoflavones Market Overview, 20208.2 Middle East and Africa Isoflavones Market Revenue and Forecast, 2021-2027 (US$ Million)8.3 Middle East Africa Isoflavones Market Size and Share Outlook by Type, 2021-20278.4 Middle East Africa Isoflavones Market Size and Share Outlook by End-User, 2021-20278.5 Middle East Africa Isoflavones Market Size and Share Outlook by Country, 2021-20278.6 Key Companies in Middle East Africa Isoflavones Market9. Isoflavones Market Structure9.1 Key Players 9.2 Isoflavones Companies - Key Strategies and Financial Analysis9.2.1 Snapshot9.2.2 Business Description9.2.3 Products and Services9.2.4 Financial Analysis10. Isoflavones Industry Recent Developments11 Appendix11.1 Publisher Expertise11.2 Research Methodology11.3 Annual Subscription Plans11.4 Contact InformationFor more information about this report visit https://www.researchandmarkets.com/r/tydr0k CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Specialized Design Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
Former Leeds and England prop Peacock and his close friend Simon Dent are preparing to tackle a double marathon.
WASHINGTON — President Joe Biden and Democrats in Congress are jamming their agenda forward with a sense of urgency, an unapologetically partisan approach based on the calculation that it’s better to advance the giant COVID-19 rescue package and other priorities than waste time courting Republicans who may never compromise. The coronavirus pandemic is driving the crush of legislative action, but so are the still-raw emotions from the U.S. Capitol siege and the hard lessons of the last time Democrats had the sweep of party control of Washington. Republicans are mounting blockades of Biden’s agenda just as they did during the devastating 2009 financial crisis with Barack Obama. Democrats, in turn, are showing little patience for the GOP objections and entertaining few overtures toward compromise, claiming the majority of the country supports their agenda. With fragile majorities in the House and the Senate, and a liberal base of voters demanding action, Democrats are operating as if they are on borrowed time. For many lawmakers, it's personal. Rep. Karen Bass, D-Calif., led the George Floyd Justice in Policing Act to House passage Wednesday on the 30th anniversary of the Rodney King beating by police in Los Angeles that she thought at the time would spur policing reforms. Instead, more Black Americans and others have died in police violence, even after Floyd's death at the hands of law enforcement last summer. “It’s examples like that that lead to the urgency,” Bass said Wednesday. The start of the first congressional session of the Biden administration was supposed to be a new era of bipartisan deal-making. The Senate evenly split, 50-50, and the House resting on a slim majority for Democrats set prime conditions for Biden to swoop in and forge across-the-aisle compromises. But the rush through Biden's first 100 days is shaping up as an urgent era of hardball politics, with Democrats prepared to go it alone, even if that means that changes to the Senate filibuster rules are needed to work around Republican roadblocks to legislation that many Americans support. “We said we’re going to do X, Y and Z, but we didn’t say we were going to be magicians,” said House Majority Leader Steny Hoyer, D-Md. “We can’t magically make the Republicans be for what the people are for.” Days before Biden entered office, White House chief of staff Ron Klain highlighted the urgency with which the incoming administration would seek to act. “We face four overlapping and compounding crises: the COVID-19 crisis, the resulting economic crisis, the climate crisis, and a racial equity crisis,” he wrote in a memo. “All of these crises demand urgent action.” From his first hours in office, Biden sought to take deliberate steps to deliver relief but also to raise awareness about those and other priorities on the theory that moving urgently would increase public support and raise pressure on Republican lawmakers who might stand in the way. And within the White House there's another kind of urgency: Biden has staffed his administration with veterans of government service who are not looking to stick around that long. Some aides are open about their commitments to help Biden for just a year before returning to private-sector jobs. Biden’s $1.9 trillion American Rescue Plan is coursing ahead on party line votes under budget rules that will allow Senate passage by a simple 51-vote threshold, denying Republicans the ability to block the bill with a filibuster that would take 60 votes to overcome. House leaders have reworked this month’s schedule for legislation to include voting rights, gun background checks and immigration in the queue — many of them do-overs of bills blocked last session by President Donald Trump and Senate Republicans. They still face a long haul to becoming law without GOP support in the Senate. House Speaker Nancy Pelosi and Senate Majority Leader Chuck Schumer often hark back to the lessons of 2009, when Obama took office during the financial crisis and Democrats cut back the recovery package to win a few Republican votes only to face an onslaught of attacks against the bill. Many of the same Democrats in leadership today are unwilling to risk a repeat, especially as Treasury Secretary Janet Yellen and other economists now say that paring back the 2009 rescue package stunted the recovery. “One of the biggest lessons that Republicans learned in the '09 and '10 era is they could basically obstruct everything and not suffer at the ballot box,” said Tre Easton, a senior adviser at the liberal Battle Born Collective. The strategy is on display again. House Republicans used procedural objections to stall the COVID-19 package until well past midnight late last week after a marathon rules session spilled voting into early Saturday. Senate Republicans are now threatening similar delays. “We’ll be fighting this in every way that we can,” Senate Republican leader Mitch McConnell said about the COVID-19 package. McConnell wants Senate Republicans to vote in lockstep against the virus aid, calling it a bloated liberal wish list, following the lead of House Republicans who gave it zero support. That leaves Democrats negotiating with themselves on the COVID-19 package, with Biden warning they won’t like every aspect as he courts centrists. Progressives are being forced to abandon, for now, a provision to lift the federal minimum wage to $15 an hour. On Wednesday, Democrats decided to more narrowly target $1,400 direct payments to households. Yet Democrats are holding together, so far, because there’s also the urgency that was not readily apparent until Biden was sworn into office. Perhaps nothing has stiffened the Democratic resolve like the deadly Jan. 6 siege of the Capitol, which carved new fault lines between those who confirmed the presidential election results and those willing to side with the mob seeking to overturn Trump’s defeat to Biden. Democratic lawmakers who arrive at the fenced-in Capitol under the watchful protection of armed National Guard troops appear to have “zero” patience, as one aide put it, for engaging with Republicans — some of whom still question the election results. A new threat of violence sent lawmakers to wrap up work for the week late Wednesday. Republicans are protesting the partisan start, even though they relied on a similar budget mechanism to try to pass Trump-era priorities. They set out to repeal “Obamacare,” an effort that shockingly failed when Sen. John McCain gave it a thumbs-down vote. Later they passed $2 trillion in tax cuts on a party-line vote. The third-ranking Republican, Sen. John Barrasso of Wyoming, said Biden should go back to his campaign and inauguration themes of bipartisanship “and try to live up to it.” But a generation of House leaders who have served decades with Biden and are nearing retirement are increasingly pushing for Senate filibuster rules changes to counter Republican opposition. Rep. James E. Clyburn, D-S.C., the majority whip, said of Republican obstruction: "If that’s what they're going to do, then they're going to have to live with it, because we’re going to serve it up.” Lisa Mascaro And Zeke Miller, The Associated Press
The plaque from the street that is home to the famous recording studios, and featured on a Beatles album cover, smashed expectations at the sale.
Berlin-based Rise Pictures and Simonsays Pictures in Stuttgart are partnering on a new dark supernatural comedy series about a secretive, multinational corporation established by the Grim Reaper in an effort to more efficiently collect the souls of the dearly departed. “Grim Inc.” revolves around the mysterious enterprise founded by Death some 70 years ago. At […]
Egypt on Thursday expanded its coronavirus vaccination rollout to include the elderly and people with chronic diseases after several weeks of vaccinating medical staff, the cabinet said. Nearly 153,000 people have applied for vaccinations since Sunday when the North African country opened online registration, the cabinet said in a statement. Egypt, the Arab world's most populous country with more than 100 million, has prepared 40 vaccination centres and plans to increase that number after the arrival of more vaccine batches, Prime Minister Mostafa Madbouly said.
Britain, France and Germany have scrapped a U.S.-backed plan for the U.N. nuclear watchdog's board to criticise Iran for scaling back cooperation with the agency, diplomats said on Thursday, amid concerns about efforts to revive Iran's nuclear deal. The European powers, all parties to the 2015 nuclear deal, have been lobbying for the International Atomic Energy Agency's 35-nation Board of Governors to adopt a resolution at this week's quarterly meeting expressing concern at Iran's latest breaches of the deal and calling on it to undo them. However, Iran has bristled at the prospect, threatening to end a recent agreement with the IAEA that limits the impact of its latest moves and enables monitoring of its facilities to continue in a black-box-type arrangement for up to three months.
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree TalkTalk Telecom Group plc (c) Name of the party to the offer with which exempt principal trader is connected: Offeree - TalkTalk Telecom Group plc (d) Date dealing undertaken: 03 March 2021 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received (GBP) Lowest price per unit paid/received (GBP) Ordinary Shares Purchase 1,321 96.850 p 96.850 p (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (GBP) Ordinary Shares Swap Increasing a Short Position 275 96.858 p Ordinary Shares Swap Increasing a Short Position 1,046 96.858 p (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” Date of disclosure: 04 March 2021 Contact name: Mohammed Abdul Qader Telephone number: 0207 088 2000 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Privately held companies love bull markets, and with stock markets near all-time highs, it's been a great time for those private businesses to come public. Rather than going through the traditional initial public offering (IPO) process, which can be painful and long, many companies have chosen instead to come public using a special purpose acquisition company (SPAC). High-profile SPAC wins got investors truly excited about the prospects for investing in the next big disruptive company before anyone else got a chance.
The indigenous efforts to build complex instruments like ADFOSC in India is an important step to become 'Aatmanirbhar' in the field of astronomy and astrophysics.
Hungary is widely expected to announce further lockdown measures on Thursday after a surge in new coronavirus cases that pose a challenge for Prime Minister Viktor Orban, who had raised hopes of a gradual lifting of restrictions from April. Orban, who faces an election battle early next year, has been balancing coronavirus curbs with keeping shops and industries open to try to limit the economic effects of the pandemic, which caused a 5% recession last year. But Hungary reported 6,278 new COVID-19 cases on Thursday, its highest daily tally in three months, mainly because of a spread of the British variant of the virus.
MOSCOW — The European Medicines Agency said it has started a rolling review of Sputnik V, many months after the vaccine was first approved for use in Russia and after dozens of countries around the world have authorized it. In a statement Thursday, the European regulator said the review is based on results from lab studies and research in adults, which suggests the vaccine may help protect against coronavirus. Despite skepticism about Russia’s hasty introduction of the vaccine, which was rolled out before it had completed late-stage trials, the vaccine appears to be safe and effective. According to a study published in the journal Lancet, Sputnik V was about 91% effective in preventing people from becoming severely ill with COVID-19. The EMA has not set a date for when its expert group might meet to assess Sputnik V data to decide if it should be approved across the European Union, but the rolling review process is meant to expedite the authorization process, which can typically take several months. The Associated Press
Chloe Zao’s awards season favorite “Nomadland” will premiere on Disney Plus Star in the U.K. on April 30, Searchlight Pictures has announced. The film will be available for theatrical release in the U.K. and Ireland once cinemas reopen. The earliest cinemas are expected to open in the U.K. is May 17. More to follow
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "2021 Isolates and Concentrates Oryzenin Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive research with in-depth data and contemporary analysis of Isolates and Concentrates Oryzenin Market at a global, regional and key country level, split by different sub-segments of the industry. This report presents growth projections in the Isolates and Concentrates Oryzenin Market between 2021 and 2027 for companies operating across different types, applications, and end-user verticals.Isolates and Concentrates Oryzenin Market is quickly reaching its pre-COVID levels and a healthy growth rate is expected over the forecast period driven by the V-shaped recovery in most of the developing nations.Key strategies of companies operating in Isolates and Concentrates Oryzenin Market Industry are identified as showcasing their contactless manufacturing and delivery methods, highlighting USP statements, focus on product packaging, and increased the presence of products on online platforms.The food industry is set to experience a few changes in 2021 due to the increased consciousness of consumers in selecting food. This inclination towards sustainable, regenerative, plant-based food and demand for foods and beverages with immunity-boosting ingredients is driving the demand for these products and their constituents. Do It Yourself (DIY) trend has seen huge momentum during Corona times and is expected to continue in 2021.Considering the rapidly changing market landscape, companies are changing their perspectives on expanding beyond traditional markets. In addition to focusing on widening applications, introducing new product portfolios, most food and beverage companies are planning to capture domestic and international markets.Fast pace recovery of developing economies leading to increased disposable income will support the Isolates and Concentrates Oryzenin Market demand between 2021 and 2027.Lockdowns across the globe in 2020 and continuing restrictions in 2021 disrupted the supply chain posing challenges for manufactures in the Isolates and Concentrates Oryzenin Market. Intense competition, pricing issues, and shifting consumer preferences will continue to put pressure on vendors' profit margins.Short-term and long-term trends affecting the market landscape are included in the research. Further, market drivers, restraints, and potential opportunities are also provided in the report.The Isolates and Concentrates Oryzenin report computes the 2020 market value in revenue terms based on the average Isolates and Concentrates Oryzenin prices and sales/revenue models of key companies operating in the Isolates and Concentrates Oryzenin Market Industry. The study forecasts the market size to 2027 for different types of Isolates and Concentrates Oryzenin and provides respective market share and growth rates.The study discusses technological innovations and the potential shift in demand among various products in the Isolates and Concentrates Oryzenin Market, over the forecast period. The leading five companies in the Isolates and Concentrates Oryzenin Market Industry together with their products, key strategies, and comparisons are provided.The Isolates and Concentrates Oryzenin Market size, share, and outlook across different types and applications are provided at geographic levels of North America, Asia Pacific, Europe, Middle East Africa, South and Central America. Further, country-level Isolates and Concentrates Oryzenin Market value is also provided.All recent developments in Isolates and Concentrates Oryzenin Market Industry including mergers, acquisitions, contract awards, licenses, product launches, and expansion plans are included in the report. Base Year - 2020; Forecast period: 2021 - 2027Publication frequency - Every six monthsResearch Methodology - Data triangulation with top-down and Bottom-up approach are used for market size Scope of the Report Global Isolates and Concentrates Oryzenin Market Industry size, 2020-2027Market trends, drivers, restraints, and opportunitiesPorter's Five forces analysisTypes of Isolates and Concentrates Oryzenin, 2020-2027Isolates and Concentrates Oryzenin applications and end-user verticals market size, 2020-2027Isolates and Concentrates Oryzenin Market size across countries, 2020-20275 leading companies in the industry - overview, key strategies, financials, and productsLatest market news and developments Key Topics Covered: 1. Table of Contents2. Isolates and Concentrates Oryzenin Market Latest Trends, Drivers and Challenges, 2020 -20272.1 Isolates and Concentrates Oryzenin Market Overview2.2 Post COVID Strategies of Leading Isolates and Concentrates Oryzenin Companies2.3 Isolates and Concentrates Oryzenin Market Insights, 2021-20272.3.1 Leading Isolates and Concentrates Oryzenin types, 2021-20272.3.2 Leading Isolates and Concentrates Oryzenin End-User industries, 2021-20272.3.3 Fast-Growing countries for Isolates and Concentrates Oryzenin sales, 2021-20272.4 Isolates and Concentrates Oryzenin Market Drivers and Restraints2.4.1 Isolates and Concentrates Oryzenin Demand Drivers to 20272.4.2 Isolates and Concentrates Oryzenin Challenges to 20272.5 Isolates and Concentrates Oryzenin Market-Five Forces Analysis2.5.1 Isolates and Concentrates Oryzenin Industry Attractiveness Index, 20202.5.2 Threat of New Entrants2.5.3 Bargaining Power of Suppliers2.5.4 Bargaining Power of Buyers2.5.5 Intensity of Competitive Rivalry2.5.6 Threat of Substitutes3. Global Isolates and Concentrates Oryzenin Market Value, Market Share, and Forecast to 20273.1 Global Isolates and Concentrates Oryzenin Market Overview, 20203.2 Global Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)3.3 Global Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20273.4 Global Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20273.5 Global Isolates and Concentrates Oryzenin Market Size and Share Outlook by Region, 2021-20274. Asia Pacific Isolates and Concentrates Oryzenin Market Value, Market Share and Forecast to 20274.1 Asia Pacific Isolates and Concentrates Oryzenin Market Overview, 20204.2 Asia Pacific Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)4.3 Asia Pacific Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20274.4 Asia Pacific Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20274.5 Asia Pacific Isolates and Concentrates Oryzenin Market Size and Share Outlook by Country, 2021-20274.6 Key Companies in Asia Pacific Isolates and Concentrates Oryzenin Market5. Europe Isolates and Concentrates Oryzenin Market Value, Market Share, and Forecast to 20275.1 Europe Isolates and Concentrates Oryzenin Market Overview, 20205.2 Europe Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)5.3 Europe Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20275.4 Europe Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20275.5 Europe Isolates and Concentrates Oryzenin Market Size and Share Outlook by Country, 2021-20275.6 Key Companies in Europe Isolates and Concentrates Oryzenin Market6. North America Isolates and Concentrates Oryzenin Market Value, Market Share and Forecast to 20276.1 North America Isolates and Concentrates Oryzenin Market Overview, 20206.2 North America Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)6.3 North America Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20276.4 North America Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20276.5 North America Isolates and Concentrates Oryzenin Market Size and Share Outlook by Country, 2021-20276.6 Key Companies in North America Isolates and Concentrates Oryzenin Market7. South and Central America Isolates and Concentrates Oryzenin Market Value, Market Share and Forecast to 20277.1 South and Central America Isolates and Concentrates Oryzenin Market Overview, 20207.2 South and Central America Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)7.3 South and Central America Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20277.4 South and Central America Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20277.5 South and Central America Isolates and Concentrates Oryzenin Market Size and Share Outlook by Country, 2021-20277.6 Key Companies in South and Central America Isolates and Concentrates Oryzenin Market8. Middle East Africa Isolates and Concentrates Oryzenin Market Value, Market Share and Forecast to 20278.1 Middle East Africa Isolates and Concentrates Oryzenin Market Overview, 20208.2 Middle East and Africa Isolates and Concentrates Oryzenin Market Revenue and Forecast, 2021-2027 (US$ Million)8.3 Middle East Africa Isolates and Concentrates Oryzenin Market Size and Share Outlook by Type, 2021-20278.4 Middle East Africa Isolates and Concentrates Oryzenin Market Size and Share Outlook by End-User, 2021-20278.5 Middle East Africa Isolates and Concentrates Oryzenin Market Size and Share Outlook by Country, 2021-20278.6 Key Companies in Middle East Africa Isolates and Concentrates Oryzenin Market9. Isolates and Concentrates Oryzenin Market Structure9.1 Key Players 9.2 Isolates and Concentrates Oryzenin Companies - Key Strategies and Financial Analysis9.2.1 Snapshot9.2.2 Business Description9.2.3 Products and Services9.2.4 Financial Analysis10. Isolates and Concentrates Oryzenin Industry Recent Developments11 Appendix11.1 Publisher Expertise11.2 Research Methodology11.3 Annual Subscription Plans11.4 Contact InformationFor more information about this report visit https://www.researchandmarkets.com/r/b4uvn1 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900